Los Angeles, California, January 11, 2018 - The U.S. Food and Drug Administration has approved an antipsychotic, aripiprazole, as the first drug to contain a “digital ingestion tracking system” that can tell whether the drug has been taken—a technology that even a leading U.S. psychiatrist likened to “a biomedical Big Brother.” The Citizens Commission on Human Rights (CCHR), an international mental health industry watchdog, says Congress should investigate how the FDA could approve such technology to be used on the very same antipsychotic drug that the Agency already warned can cause damaging compulsive behavior, requiring a Black Box warning. Despite the agency’s most severe warning, it is allowing the antipsychotic to be the first to utilize the digital tracking that could be used to enforce patients to take the drug, CCHR says.
The new tracking system works by sending a message from the pill’s sensor to a wearable patch. The patch transmits the information to a mobile application so that patients can track the ingestion of the drug on their smart phone. Caregivers and physicians may also access the information through a web-based portal.
The New York Times has cited concerns about the technology, headlining their article in November, “First Digital Pill Approved to Worries about Biomedical ‘Big Brother’.” Other media said it sparked worries about granting “Big Brother” the ability to know if you’re “properly medicated.” The New York Times also pointed out that insurers may push medical practitioners to prescribe digital pills so they make certain drugs are being used. A digital script might also become a condition for parole or releasing patients from psychiatric facilities.
Greater oversight is needed on psychiatric research that historically has been used to develop techniques to control behavior, not to cure.
While the patient is supposed to consent to the digital pill, the technology also carries risks for patient privacy if there are breaches of medical data or unauthorized use as a surveillance tool, said James Giordano, a professor of neurology at Georgetown University Medical Center. “Could this type of device be used for real-time surveillance? The answer is of course it could,” said Giordano.
CCHR says approving an antipsychotic for this technology is egregious, given aripiprazole’s already known serious adverse effects that include increased risk of death in elderly patients. And while not approved for use in dementia patients, the drug can be prescribed off-label. Aripiprazole has already become one of the hottest off-label scripts in the country, looping in large groups of new patients, according to a 2015 exposé in the Milwaukee Magazine.
Last year’s FDA Black Box warning on the antipsychotic was based on approximately 200 reported cases of compulsive gambling, eating, shopping, or sexual behaviors by patients taking aripiprazole, according to Consumer Safety. The drug can also cause some patients to gain as much as a pound per week while taking it and can cause hyperglycemia (an increase in blood sugar). Both hyperglycemia and rapid weight gain are risk factors for type 2 diabetes.
A Lucrative Drug Business
In 2007, the FDA also approved aripiprazole as an “add-on” drug to antidepressants for treatment of depression. It helped make the antipsychotic America’s highest-grossing drug. Between April 2013 and March 2014, it racked up about $6.9 billion in U.S. sales, more than any other prescription drug. Antidepressants, with which aripiprazole is combined, are one of the three most commonly used drug classes in the U.S., according to the Centers for Disease Control and Prevention (CDC).
Now, with the approval of the digestion tracking system, CCHR says millions of people prescribed the drug could be tracked to ensure they stay on it. At more than $450 a bottle even without the digital tracker, the powerful antipsychotic was prescribed to nearly 9 million Americans in 2014.
Psychiatry Creates Brave New World in Mental Health
Today, research is also in the pipeline to replace drugs with a medical implant that is attached to the nerve to block or alter signals in the nerve. It is called bioelectronic medicines or as GlaxoSmithKline coined, “electroceuticals.” In March 2016, The Wall Street Daily reported, “A number of pharmaceutical companies will eventually transform into bioelectronics companies…Welcome to the brave new world of neuromodulation and electroceuticals.”
In 2015, a Forbes report said that investors had poured $3.3 billion into firms that are developing drugs for brain-destroying or psychiatric illnesses, more than in any of the last ten years, quoting NeuroPerspective. Whether nerve-trapping devices or drugs, the bottom line is that the 79 million Americans taking psychotropic drugs are now at risk of serious effects, yet the FDA—buoyed by psychiatric research—keeps approving these drugs and other technology to treat and control some of our most vulnerable, while the adverse effects are ignored, CCHR asserts. The group says the digital tracking pill is but the tip of the iceberg.
CCHR says greater oversight is needed on psychiatric research that historically has been used to develop techniques to control behavior, not to cure. The recently released Netflix documentary series Wormwood is evidence of this and the disastrous results. And why “digital sensors,” electroshock treatment and electronic implants should never be allowed in the field of mental health. With the FDA complicit in this, CCHR says Congress should have a tighter reign over what the Agency is approving.
As a nonprofit, CCHR relies on memberships and donations to help it to provide information about psychotropic drugs and other psychiatric treatments that are not generally publicized. It has already been responsible for helping get over 180 laws enacted, including the banning of electroshock treatment on children and the 2004 Federal Child Medication Safety Amendment that prohibits schools from forcing children onto psychotropic drugs as a requisite for their education. Click here to support the cause.
 “FDA approves pill with sensor that digitally tracks if patients have ingested their medication,” FDA News release, 13 Nov. 2017, https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm584933.htm; Peter Dockrill, “FDA Approves a Trackable 'Digital Pill' That Delivers Schizophrenia Medication,” Science Alert, 15 Nov. 2017, https://sciencealert.com/fda-approved-first-digital-pill-embedded-tracking-system-abilify-mycite.
 “Why Are People Filing Abilify Lawsuits?,” Consumer Safety, https://www.consumersafety.org/legal/abilify-lawsuit/.
 Op. cit. FDA News release, 13 Nov. 2017.
 Matthew Perrone, “First digital pill approved despite worries about biomedical Big Brother,” SFGate, 14 Nov. 2017, http://www.sfgate.com/business/article/First-digital-pill-approved-despite-worries-about-12357627.php.
 “Why Are People Filing Abilify Lawsuits?,”Consumer Safety, https://www.consumersafety.org/legal/abilify-lawsuit/.
 Matt Hrodey, “The Selling of Abilify,” Milwaukee Magazine, 4 May 2015, https://www.milwaukeemag.com/the-selling-of-abilify/.
 Op. cit. “Why Are People Filing Abilify Lawsuits?”
 Op. cit. Matt Hrodey.
 https://www.psychiatry.org/news-room/apa-blogs/apa-blog/2017/09/antidepressant-use-on-the-rise; Centers for Disease Control and Prevention. NCHS Data Brief No. 283: Antidepressant Use Among Persons Aged 12 and Over: United States, 2011–2014, August 2017, http://www.cdc.gov/nchs/data/databriefs/db283.pdf.
 Susan Perry, “Has the overprescribing of antipsychotics become the new normal?” Minnesota Post, 18 May, 2015, https://www.minnpost.com/second-opinion/2015/05/has-overprescribing-antipsychotics-become-new-norma.
 Devin Coldewey, “Wireless Medical Implant Is Smaller Than a Grain of Rice,” 20 NBC News, May 2014, http://www.nbcnews.com/tech/innovation/wireless-medical-implant-smaller-grain-rice-n109431.
 “GSK Sets 2017 Trials For Electroceuticals For Chronic Diseases,” Med Device Online, 15 March 2016, http://www.meddeviceonline.com/doc/gsk-sets-trials-for-electroceuticals-for-chronic-diseases-0001.
 “Electroceuticals: The Future of Medicine,” The Wall Street Daily (online), 10 Mar. 2016, http://www.wallstreetdaily.com/2016/03/10/electroceuticals-glaxosmithkline-gsk/.
 Matthew Herper, “The Coming Boom In Brain Medicines,” Forbes, 2 Mar. 2015, http://www.forbes.com/sites/matthewherper/2015/02/11/brain-boom-the-drug-companies-bringing-neuroscience-back-from-the-brink/#7d3ea7b52a22.
 JoAnna Wendel, “Innovations in neuroscience trigger shifting views in the treatment of mental illness,” Genetic Literacy Project, 26 Sept. 2013.
 “Cell transplants may be a novel treatment for schizophrenia: Rodent research suggests feasibility of restoring neuron function,” University of Texas Health Science Center San Antonio, 9 Sept. 2013, http://www.eurekalert.org/pub_releases/2013-09/uoth-ctm090913.php.
 David Gutierrez “Orwellian nightmare: scientists now able to create or erase memories at will,” Natural News, 23 June 2014, http://www.naturalnews.com/045690_memory_implants_induced_loss_medical_ethics.html; “How to erase a memory –- and restore it: Researchers reactivate memories in rats,” Science Daily, 1 Jun 2014, https://www.sciencedaily.com/releases/2014/06/140601150633.htm.
“Who Holds the Clicker?: Neuroscientists hope that brain implants can treat intractable mental illness. But who would control those brave new minds?”, Mother Jones, Nov. 2005, http://www.motherjones.com/politics/2005/11/who-holds-clicker/; “Implant can scan, stimulate brain,” GMA News Online, 16 Aug 2013, http://www.gmanetwork.com/news/scitech/technology/322351/implant-can-scan-stimulate-brain/story/.
 “Can anesthesia replace shock therapy as depression treatment,” KSL.com, Utah, 19 July 2013, http://www.ksl.com/?sid=26214243&nid=148.
Source: Citizens Commission on Human Rights International
Information contained on this page is provided by an independent third-party content provider. This Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact support [at] perpetualwire.com.